文献速递毛发、甲与色素性疾病

局部庆大霉素治疗头皮单纯性少毛症

Treatment of hereditary hypotrichosis simplex of the scalp with topical gentamicin.
PubMed 文献 · Br J Dermatol · 2019-12-26

本研究探讨局部庆大霉素对携带CDSN无义突变的头皮单纯性少毛症(HSS)患者的疗效。体外实验显示庆大霉素可诱导通读活性并恢复角化桥粒蛋白翻译;小规模临床试验中4例患者头皮局部治疗6个月,脱发严重程度工具评分显著改善。结论提示局部庆大霉素可作为HSS的潜在治疗选择。

要点

  • HSS常由CDSN显性无义突变引起,突变蛋白干扰毛囊周期。
  • 庆大霉素在体外可通读CDSN无义突变并恢复全长角化桥粒蛋白合成。
  • 4例患者局部庆大霉素治疗6个月,脱发严重程度工具评分显著改善。

核心结论

  • 局部庆大霉素应被视为头皮单纯性少毛症(HSS)的潜在治疗方式。

研究设计与样本

  • 体外研究采用绿色荧光报告基因检测、共聚焦显微镜和Western blot分析庆大霉素对CDSN无义突变的通读能力。
  • pilot临床试验中4例携带CDSN复发突变的HSS患者头皮局部接受庆大霉素治疗6个月。

主要发现

  • 报告基因检测显示庆大霉素对导致HSS的无义突变具有通读活性。
  • 庆大霉素可恢复来自HSS患者原代角质形成细胞中的角化桥粒蛋白翻译。
  • 4例患者局部治疗6个月后,脱发严重程度工具评分显示显著改善。

关键数值与推荐

  • 体外实验证实庆大霉素诱导CDSN无义突变的翻译通读。
  • 临床试验中4例患者局部治疗6个月,脱发严重程度工具评分显著改善。

临床怎么用

  • 对于携带CDSN无义突变的HSS患者,可考虑局部庆大霉素作为潜在治疗选择。

局限性

  • 临床试验仅为小样本试点研究(4例患者),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypotrichosis simplex of the scalp (HSS) is characterized by progressive loss of scalp hair that results in almost complete baldness at a young age. HSS is often caused by dominant nonsense mutations in CDSN encoding corneodesmosin, leading to the formation of an amyloid-like material, which interferes with normal hair follicle cycle. OBJECTIVES: As gentamicin has been shown to mediate ribosomal read-through, we aimed to ascertain its therapeutic efficacy in a small series of patients carrying a recurrent mutation in CDSN . METHODS: We used a green fluorescence reporter assay system, confocal microscopy and Western blot analysis to ascertain in vitro the ability of gentamicin to induce translational read-through across a causative CDSN mutation. RESULTS: Using a reporter assay, we initially showed that gentamicin induces read-through activity across an HSS-causing nonsense mutation. Gentamicin was further shown to rescue corneodesmosin translation in primary keratinocytes obtained from a patient with HSS. To validate the in vitro data, we conducted a pilot clinical trial where the scalp of four patients was treated topically with gentamicin for 6 months, demonstrating significant improvement as ascertained by the Severity of Alopecia Tool score. CONCLUSIONS: Our findings indicate that topical gentamicin should be considered as a potential therapeutic modality in HSS. What's already known about this topic? Hypotrichosis simplex of the scalp (HSS) is caused by nonsense mutations in CDSN encoding corneodesmosin. The mutant corneodesmosin has been hypothesized to be toxic to the hair follicles, leading to hypotrichosis. Disorders caused by nonsense mutations are amenable to ribosomal read-through using gentamicin. What does this study add? Gentamicin enhanced read-through activity and promoted full-length corneodesmosin synthesis in primary keratinocytes derived from patients carrying a nonsense mutation in CDSN. Topical treatment with gentamicin was found to rescue the hypotrichosis phenotype partially in four patients with HSS. What is the translational message? Topical gentamicin should be considered as a potential treatment for HSS.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Peled A, Samuelov L, Sarig O, et al. Treatment of hereditary hypotrichosis simplex of the scalp with topical gentamicin. Br J Dermatol. 2019. PMID: 31746457. doi:10.1111/bjd.18718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。